The window for the public to weigh in on whether large compounding facilities should ever again be allowed to make semaglutide and tirzepatide from raw ingredients closed at 11:59 p.m. Eastern Time on July 30. FDA is now reviewing what it received, and has announced no date for a decision.
That is the entire procedural news, and it matters more than its dryness suggests. The proposal, published in the Federal Register on May 1 and extended by 30 days in June after a request for more time, would keep semaglutide, tirzepatide and liraglutide off the 503B bulks list permanently. If finalized as written, it closes the last broad legal route for industrial-scale compounding of the drugs sold as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza and Saxenda.
For households currently paying a few hundred dollars a month for a compounded version instead of a four-figure list price, the question is not whether the rule is fair. It is what the timeline actually is, and the honest answer is that nobody outside FDA knows.
What the 503B Bulks List Is and Why FDA Wants These Drugs Off It
Compounding pharmacies exist to solve real problems, such as making a liquid version of a pill for a child who cannot swallow tablets. Federal law limits how far that can go when an approved commercial product already exists.
Under section 503B of the Federal Food, Drug, and Cosmetic Act, large outsourcing facilities may only compound from bulk active ingredients in two situations: the ingredient appears on the 503B bulks list, meaning FDA has found a clinical need for it, or the finished drug sits on FDA's shortage list at the time of compounding. Both doors have been closing. Tirzepatide came off the shortage list in December 2024 and semaglutide followed in February 2025.
FDA's April 30 announcement said the agency reviewed the nominations it received and found insufficient evidence of clinical need for any of the three. Commissioner Marty Makary framed the standard plainly, saying outsourcing facilities "cannot lawfully compound using bulk drug substances unless there is a clear clinical need."
The word doing the work in that sentence is clinical. FDA's position, as reflected in the notice, is that affordability and insurance coverage are real problems addressed by other policy tools, not evidence of clinical need. That interpretation is the crux of what commenters spent three months arguing about.
What Closing the Window Changes, and What It Does Not
Nothing about a patient's prescription changed on July 31. The comment period ending is a procedural step, not a ban taking effect.
FDA said in its extension notice that granting 30 days rather than the 60 requested balanced adequate time to comment against avoiding significant delay of agency action, which signals the agency is not planning to sit on the docket indefinitely. Even so, no statutory clock forces a decision by a particular date, and the agency has not published one.
What has already changed, and changed well before this docket, is the legal footing of most compounded GLP-1 supply. With neither the shortage pathway nor the bulks list available, the Alliance for Pharmacy Compounding has told its own members it knows of no authority under which a 503B facility may currently prepare drugs containing semaglutide or tirzepatide. Litigation brought by the Outsourcing Facilities Association failed to secure a preliminary injunction. Products still being sold are frequently marketed as different formulations, with added ingredients or alternate chemical forms, rather than copies.
Comments filed in the docket, including one submitted on July 28 by the Partnership for Safe Medicines supporting the exclusion, become part of the administrative record and would be part of any judicial review.
Why the Substitutes Now on Offer Carry Their Own Problem
The practical risk for households is not the drought that a final rule might create. It is the workaround market that already exists.
Because a straight copy is no longer defensible, some sellers have moved to versions that differ from the approved drug: salt forms such as semaglutide sodium, combinations with vitamin B12 or other additives, and sublingual drops or dissolving tablets. Stanford Medicine's clinicians laid out the concerns in a July explainer. Michael Blyumin, PharmD, an ambulatory clinical care pharmacist there, was blunt about one category, saying "nobody legitimate makes sublingual semaglutide."
Dosing is the other exposure. Approved products come in prefilled single-dose pens. Many compounded versions arrive in multidose vials the patient draws from, and FDA has documented cases in which people administered ten to twenty times the intended dose through simple measurement error. Concentrations vary between products, so units are not interchangeable.
The people most exposed are cash-paying patients without GLP-1 coverage, patients buying from telehealth platforms with limited follow-up, and anyone taking these drugs for type 2 diabetes rather than weight management, where an interruption in supply carries immediate metabolic consequences.
What Patients Using a Compounded GLP-1 Should Do Now
No one should stop a medication abruptly based on a regulatory news story, and that caution applies with particular force to anyone using a GLP-1 for diabetes.
The reasonable step is to schedule a conversation with a prescribing clinician about transitioning to an approved product before supply becomes an issue, rather than after. That conversation is not always simple, because the dose actually delivered by a compounded product may not be clear, and clinicians generally restart at a lower dose and titrate up rather than matching a reported number.
On cost, the options worth asking about are manufacturer direct cash pricing and savings programs, Medicare out-of-pocket caps for those who qualify, and older generic weight management medications that cost substantially less. Patients who must continue with a compounded product should confirm it comes from a registered outsourcing facility rather than an unlicensed online seller, and FDA's BeSafeRx program can help identify licensed pharmacies by state. A seller that does not require a prescription, ships from outside the United States, or delivers unlabeled or expired packaging is a reason to stop, not a bargain.
Severe abdominal pain radiating to the back, fainting, confusion, or vomiting that worsens rather than eases over time warrants prompt medical evaluation.
What Happens Next
FDA will review the comments and issue a final determination on the three substances. The agency has not committed to a date. Patient-specific compounding under section 503A remains legal within narrow limits, so a final exclusion would not eliminate every compounded product, but it would remove the scale.
Developing Story Timeline
July 30, 2026, 11:59 p.m. ET: Federal comment period closed on FDA's proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list.
June 26, 2026: FDA published a notice extending the comment period by 30 days after receiving a request for additional time.
May 1, 2026: FDA published the notice in the Federal Register opening a 60-day comment period on the proposed exclusion.
April 30, 2026: FDA announced the proposal, finding no clinical need for outsourcing facilities to compound the three substances from bulk drug substances.
Frequently Asked Questions
What happened on July 30? The federal public comment period closed on FDA's proposal to keep semaglutide, tirzepatide, and liraglutide off the 503B bulk list. FDA is now reviewing comments.
Does this mean compounded GLP-1s are banned now? No. The comment period closing is a procedural step. FDA has not issued a final determination and has not announced a timeline.
What is the 503B bulks list? A federal list of bulk active ingredients that large outsourcing facilities may legally use in compounding. Without a listing or an active shortage, that route is generally unavailable.
Why did FDA propose the exclusion? The agency found insufficient evidence of clinical need now that approved products are commercially available and the shortages have resolved.
Does cost count as a clinical need? Under FDA's stated interpretation, no. The agency treats affordability as a separate policy question from the statutory clinical need standard.
Should I stop my compounded medication? Not on your own, and especially not if you take it for diabetes. Talk with a prescribing clinician about a supervised transition and lower-cost approved options.
How do I know if a seller is legitimate? A legitimate source requires a prescription, is licensed in the United States, and ships properly labeled product with an expiration date. FDA's BeSafeRx tool can help verify online pharmacies.
